FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Study Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

Conditions

Healthy Participants Atopic Dermatitis

Interventions / Drugs

PF-07832837 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment119 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.189872+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.